Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 17Lung Neoplasms 14Neoplasms 13Breast Neoplasms 9Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Melanoma 5Carcinoma, Transitional Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Neoplasm Metastasis 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2

Interventions

sacituzumab govitecan 1pembrolizumab 1atezolizumab 1PT-100 dipeptide 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × atezolizumab × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡